Latest KFF Health News Stories
Artificial Intelligence May Influence Whether You Can Get Pain Medication
To contain the opioid crisis, health and law enforcement agencies have turned to technology to monitor doctor and patient prescription data. Experts have raised questions about how these systems work and worry about their accuracy and potential biases. Some patients and doctors say they’re being unfairly targeted.
5 Things to Know About the New Drug Pricing Negotiations
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
Sin barreras, los precios de algunos medicamentos existentes se han disparado, incluso cuando han caído drásticamente en otros países. Los nuevos medicamentos tienen precios enormes, respaldados por el lobby y el marketing.
A Peek at Big Pharma’s Playbook That Leaves Many Americans Unable to Afford Their Drugs
Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development required to bring them to market nor their therapeutic value, recent research shows. Have drugmakers overplayed their hand?
KFF Health News' 'What the Health?': Abortion Pill’s Legal Limbo Continues
A federal appeals court issued a split decision on whether the abortion pill mifepristone should remain on the market — rejecting a lower court’s decision to effectively cancel the drug’s FDA approval in 2000, while ordering the rollback of more recent rules that made the drug easier to obtain. Nothing changes immediately, however, as the Supreme Court blocked the lower court’s ruling in the spring. It will be up to the high court to determine whether the pill remains available in the U.S. and under which conditions. Sarah Karlin-Smith of the Pink Sheet, Alice Miranda Ollstein of Politico, and Shefali Luthra of The 19th join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Journalists Sum Up the Costs to Patients of New Weight Loss Drugs and Hospital Mergers
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Watch: As Opioid Settlement Money Starts to Flow, States and Local Officials Debate How to Use It
PBS NewsHour featured KFF Health News’ Aneri Pattani as it reported on how this debate is playing out in North Carolina and Ohio.
New Alzheimer’s Drug Raises Hopes — Along With Questions
Clinics serving Alzheimer’s patients are working out the details of who will get treated with the new drug Leqembi. It won’t be for everyone with memory-loss symptoms.
KFF Health News' 'What the Health?': On Abortion Rights, Ohio Is the New Kansas
Nearly a year to the day after Kansas voters surprised the nation by defeating an anti-abortion ballot question, Ohio voters defeated a similar, if cagier, effort to limit access in that state. This week, they rejected an effort to raise the threshold for approval of future ballot measures from a simple majority, which would have made it harder to protect abortion access with yet another ballot question come November. Meanwhile, the number of Americans without health insurance has dropped to an all-time low, though few noticed. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Roubein of The Washington Post, and Emmarie Huetteman of KFF Health News join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews Kate McEvoy, executive director of the National Association of Medicaid Directors, about how the “Medicaid unwinding” is going, as millions have their eligibility for coverage rechecked.
Seeking Medicare Coverage for Weight Loss Drugs, Pharma Giant Courts Black Influencers
Novo Nordisk, the dominant company in the multibillion-dollar market for weight loss drugs, focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease that needs treatment.
Survey: Americans Want Weight Loss Drugs Despite High Cost
A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.
The Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The annual cost of lecanemab treatment quadruples if the expense of brain scans to monitor for bleeds and other associated care is factored in. The full financial toll likely puts it beyond reach for low-income seniors at risk of Alzheimer’s, experts say.
KFF Health News' 'What the Health?': Another Try for Mental Health ‘Parity’
President Joe Biden is kicking off his reelection campaign in part by trying to finish a decades-long effort to establish parity in insurance benefits between mental and physical health. Meanwhile, House Republicans are working to add abortion and other contentious amendments to must-pass spending bills. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Céline Gounder about her podcast “Epidemic.” The new season focuses on the successful public health effort to eradicate smallpox.
New Weight Loss Drugs Carry High Price Tags and Lots of Questions for Seniors
Although nearly 40% of Americans 60 and older are obese, Medicare doesn’t cover weight loss medications. Meanwhile, studies haven’t thoroughly examined new drugs’ impact on older adults.
KFF Health News' 'What the Health?': Let’s Talk About the Weather
It’s been the summer of broken weather records around the world — for heat, rain, and wildfire smoke — advertising the risks of climate change in a big way. But, apparently, it’s not enough to break the logjam in Washington over how to address the growing climate crisis. Meanwhile, in Texas, women who were unable to get care for pregnancy complications took their stories to court, and Congress gears up to — maybe — do something about prescription drug prices. Alice Miranda Ollstein of Politico, Shefali Luthra of The 19th, and Rachel Cohrs of Stat join Julie Rovner, KFF Health News’ chief Washington correspondent, to discuss these issues and more. Also this week, Rovner interviews Meena Seshamani, the top administrator for the federal Medicare program.
¿Cuánto costará la píldora anticonceptiva de venta libre? ¿La cubrirán los seguros?
Los defensores de la salud reproductiva celebraron esta histórica aprobación como un paso que puede ayudar a millones de personas a evitar embarazos no deseados, que ocurren casi la mitad de las veces en los Estados Unidos.
Once the New Over-the-Counter Birth Control Pill Is Available, What About Cost and Coverage?
The Food and Drug Administration’s approval is viewed as groundbreaking, but many details still must be figured out.
An Arm and a Leg: Wait, What’s a PBM?
Pharmacy benefit managers, or PBMs, are companies that negotiate the prices of prescription drugs. Hear about their role in raising drug prices and the ongoing efforts to regulate this complex industry.
What You Need to Know About the Drug Price Fight in Those TV Ads
At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients.
Why the Next Big Hope for Alzheimer’s Might Not Help Most Black Patients
Black patients and other minorities tend to be diagnosed at later stages of the disease, which would exclude them from use of Leqembi. Few Black people were included in the main trial of the drug.
